The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Novel perioperative strategies for non-small cell lung cancer
Paul van Schil, MD, PhD, University Hospital Antwerp, Antwerp, Belgium, gives an overview treatment options for non-small cell lung cancer in the perioperative setting, which should incorporate a multidisciplinary approach. New classifications guidelines have distinguished N2a and N2b, where N2b stage lung cancer will benefit from multimodal treatment including induction chemotherapy. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
